Key result
Fondaparinux resulted in a pregnancy success rate comparable to enoxaparin (59% vs 58%) in women with a history of miscarriage, infertility, and coagulant defects.
Why the study?
Does fondaparinux improve pregnancy success rates compared to enoxaparin in women with infertility or pregnancy loss and coagulant defects?
Cohort (n=110)
Does fondaparinux improve pregnancy success rates compared to enoxaparin in women with infertility or pregnancy loss and coagulant defects?
Absolute Event Rate: 59% vs 58%
In women with a history of miscarriage or infertility and coagulant defects, fondaparinux resulted in comparable pregnancy success rates to enoxaparin, though larger studies are needed.
No takes yet. Share an insight, caveat, or question.
Comparable rates support fondaparinux consideration as enoxaparin alternative; leaves open efficacy in randomized trials.
Winger et al. (2009) conducted a cohort in History of miscarriage and/or infertility and coagulant defects (n=110). Fondaparinux vs. Enoxaparin 30 mg twice daily was evaluated on Pregnancy success rate. Fondaparinux resulted in a pregnancy success rate comparable to enoxaparin (59% vs 58%) in women with a history of miscarriage, infertility, and coagulant defects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: